Figure 2.

Follow-up plan. ¹In addition to the prescribed visit schedule, local researchers may conduct more frequent inspections as per patients’ requirements, which may include blood and urine routine examination, blood biochemistry, ECG, CT, and serum tumor biomarker (within one week); ²Refers to platinum-based chemotherapy post-surgery and included information collected from the patient’s medical record; ³It should not be completed >4 weeks before enrolment, excluding exceptional cases; ⁴Required to be completed within 72 hours of the start of the cycle 1 ( ± 1D); ⁵Required to be completed within 72 hours of the start of the cycle 2 ( ± 1D); ⁶Required to be completed within 72 hours from the beginning of cycle 2 treatment D28 (± 1D); ⁷Required to be completed within 3 days pre-operation; ⁸Once every 12 weeks after maintenance treatment and once every 24 weeks after two years; ⁹Includes name, age, gender, place of origin, contact details and date of admission; ¹⁰Time interval from last inspection should be >7 days, otherwise the inspection shall be canceled; ¹¹Includes heart rate, blood pressure, pulse and respiration; ¹²Records the tumor size at least; ¹³Recommended, non-mandatory; ¹⁴The United States Eastern Cooperative Oncology Group (ECOG) physical status scores; ¹⁵Blood or urine β-HCG test; ¹⁶Completed within two weeks before enrollment; ¹⁷Includes neutrophil/platelet count, and Hb level; ¹⁸Atleast 7 days before enrollment; ¹⁹Includes measurement of serum creatinine and electrolytes, total bilirubin, ALT/AST; ²⁰Time interval from the last inspection should not be <1 week, otherwise the inspection shall be canceled; ²¹Includes measurement of creatinine, urea nitrogen, and erythrocytes; ²²Includes testing of CA125, CA199, CEA, and HE4 related markers; ²³Biopsy done by laparoscopy, laparotomy, or coarse-needle aspiration; ²⁴Primary and metastatic tumor tissues obtained by laparotomy/laparoscopic tumor reduction surgery; ²⁵Samples in 2ml EDTA anticoagulant tube were used for HRD detection before enrollment and after two courses of treatment. Samples of 10ml Streck tube were collected before enrollment, D15 and D28 of the first course of chemotherapy, D15 of the second course of chemotherapy, and before tumor reduction surgery and subsequent therapy; ²⁶Abdominal CT or MRI is recommended for evaluation instead of ultrasound alone; ²⁷If blood routine tests are abnormal during maintenance treatment, then it should be carried out every 3 days and closely monitored until it becomes normal; ²⁸The operation record of the biopsy should be sent to the research center for record within 7 days; ²⁹Surgical records should be completed within 24 hours after the surgery and sent to the research center within 7 days for reference; ³⁰All adverse events to be documented from first day of receiving niraparib to post 30 days of treatment termination; ³¹All adverse events to be documented from first day of receiving niraparib to post 30 days of treatment termination; ³²Postoperative adverse events (D1 to D28); ³³Includes FACT-O, HADS, ISI, IPAQ, and EQ-VAS; ³⁴Recurrence and time of recurrence, death and time of death, whether to continue follow-up and last follow-up time are recorded; ³⁵The last follow-up before withdrawal; ³⁶After the completion of first-line chemotherapy, patients will receive maintenance treatment with niraparib within 12 weeks. ALT/AST, alanine aminotransferase/aspartate aminotransferase; CA, cancer antigen; CEA, carcinoembryonic antigen; CT, computed tomography; D, day; ECOG, Eastern Cooperative Oncology Group; ECG, electrocardiogram; EDTA, ethylenediaminetetraacetic acid; EQ-VAS, EuroQol-visual analog scales; FACT-O, Functional Assessment of Cancer Therapy-Ovarian; HADS, Hospital Anxiety and Depression Scale; Hb, hemoglobin; β-HCG, β-human chorionic gonadotropin; HE4, human epididymis protein 4; HRD, homologous recombination deficiency; IPAQ, International Physical Activity Questionnaire; ISI, Insomnia Severity Index; MRI, magnetic resonance imaging.